11030 Background: Molecular analysis of lung AC has become standard of care for therapy selection. LCMC I collectively enrolled 1102 patients from 14 institutions with the goal of performing molecular analysis to identify therapy options. Technical aspects of the genomic testing, specimen and clinical correlations are presented. Methods: Testing for mutations in 8 genes (EGFR, KRAS, ERBB2, AKT1, BRAF, MEK1, NRAS, PIK3CA), and analysis of ALK and MET by FISH, was performed at 6 labs. Proficiency testing was carried out with blinded samples. Statistical analyses were performed for analysis completion, specimen types, testing methodology, mutation findings and clinical variables. Results: Five methodologies (SNaPshot®, mass spectrometry, Sanger +/- PNA, sizing) were variably employed for detection of mutations, with analytic sensitivities of ~5% allele frequency. All sites passed proficiency testing. 1006 specimens had at least one mutation analysis completed, 733 specimens had full genotyping results. Mutation detection rates did not vary according to method of analysis. Higher rates of specimen inadequacy were seen in biopsy (36/136; 23%) and cytology (23/65; 36%) compared to surgical (13/268; 5%) specimens at the site that analyzed the most cases. Biopsy and cytology samples, when acceptable showed no difference in mutation or FISH assay completion or positivity rate. Multiple analyses are summarized in the table. Double mutations were seen in 3.8% of samples. Conclusions: Molecular analysis is possible in a multi-institutional setting with consistent results. Cytology and small biopsy specimens were commonly sufficient for multiplex testing, although sample insufficiency was a common reason for exclusion (53% of excluded cases), and contributed to lack of assay completion. Multiple associations were identified between specific mutations and clinicopathologic features.